Genmab A/SvsThermo Fisher Scientific

GMAB and TMO stock compared: price, dividend, valuation and results, from SEC filings.

TMO

Thermo Fisher Scientific Inc

$669.54

Value $249B

-2.79%
TMO's page

Genmab A/S (GMAB) has a market value of $32.5B and Thermo Fisher Scientific (TMO) $249B. Over the last year, with dividends, GMAB moved +65.5% and TMO +17.1%. The P/E is 33.8 for GMAB and 35.2 for TMO. Dividend yield: GMAB none, TMO 0.27%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    GMAB$32.5B

    TMO$249B

    TMO is 7.7 times GMAB

  • Revenue, 12 months

    GMAB$3.7B

    TMO$47.4B

    TMO is 13 times GMAB

  • Net income, 12 months

    GMAB$963M

    TMO$7.1B

    TMO is 7.3 times GMAB

  • Operating margin

    GMAB28.6%

    TMO17.9%

    10.7 points apart

  • ROIC

    GMAB7.8%

    TMO8.2%

    0.4 points apart

  • P/E

    GMAB33.8

    TMO35.2

    About the same

  • Dividend yield

    GMAB0.0%

    TMO0.3%

    0.3 points apart

  • 5-year return

    GMAB+22.0%

    TMO+6.8%

    15.2 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

GMAB+22.0%

TMO+6.8%

5010020222023202420252026
Returns by period
PeriodGMABWith dividendsTMOWith dividends
1 year since November 19, 2025+65.5%Price +65.5%+17.1%Price +16.7%
3 years since November 20, 2023+55.9%+15.9% a yearPrice +55.9%+44.1%+13.0% a yearPrice +42.7%
5 years since November 19, 2021+22.0%+4.1% a yearPrice +22.0%+6.8%+1.3% a yearPrice +5.3%
10 years since November 21, 2016+177.1%+10.7% a yearPrice +177.1%+371.2%+16.8% a yearPrice +358.1%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

GMABGenmab A/STMOThermo Fisher Scientific

Valuation

GMABTMO
Valuation
Price$50.60$669.54
Market value$32.5B$249B
Enterprise value (EV)$35.9B$284B
P/E33.835.2
P/E, 5-year median4.832.7
P/B5.64.5
EV/EBIT33.833.5
Free cash flow yield3.5%3.1%

Results and growth

GMABTMO
Results and growth
Revenue, 12 months$3.7B$47.4B
Net income, 12 months$963M$7.1B
Free cash flow, 12 months$1.1B$7.6B
Earnings per share, 12 months$1.54$18.96
Revenue growth, year on year19.2%3.9%
Revenue growth a year, past+24.8%over 2 years+6.7%over 5 years
EPS growth a year, past-51.7%over 2 years+2.1%over 5 years

Margins and returns on capital

GMABTMO
Margins and returns on capital
Gross margin93.6%–
Operating margin28.6%17.9%
Net margin25.9%14.9%
ROIC7.8%8.2%
ROE16.5%13.4%

Balance sheet

GMABTMO
Balance sheet
Cash$1.7B$6.1B
Total debt$5.2B$41.4B
Net debt / EBITDA–3.7
Interest cover4.0×5.5×

Dividends and buybacks

GMABTMO
Dividends and buybacks
Dividend yield–0.3%
Dividend per share, 12 months–$1.84
Dividend growth a year, past–+14.3%over 5 years
Buyback yield1.3%1.2%
Shareholder yield1.3%1.5%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: GMAB or TMO

Didn't find what you were looking for?

Ask us
Which is bigger, Genmab A/S or Thermo Fisher Scientific?

By market value, Thermo Fisher Scientific ($249B) is about 7.7 times Genmab A/S ($32.5B), at today's prices.

How did GMAB and TMO stock do over the last 10 years?

Since November 21, 2016, GMAB's price moved +177.1% and TMO's +358.1%. With dividends: GMAB +177.1% (+10.7% a year), TMO +371.2% (+16.8% a year). Past returns do not predict future ones.

Which pays the higher dividend, GMAB or TMO?

The dividend yield at today's price is none for Genmab A/S and 0.27% for Thermo Fisher Scientific. Over the last twelve months they paid – and $1.84 per share.

What is the P/E of GMAB and TMO?

At today's price, the P/E is 33.8 for GMAB and 35.2 for TMO. The median of the last five years was 4.8 and 32.7, which shows where each stands against its own past.

Which has the higher profit margins, Genmab A/S or Thermo Fisher Scientific?

Over the last twelve months, the net margin was 25.9% for Genmab A/S and 14.9% for Thermo Fisher Scientific, and the operating margin 28.6% and 17.9%. Revenue was $3.7B and $47.4B.

Which is the better investment, Genmab A/S or Thermo Fisher Scientific?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.